ReviewCurrent medicinal chemistry2026
Hybrids/Conjugates/Chimera Drugs-Antimicrobial Hybrids: Antibiotics, Antifungals, Antituberculars, Antimalarials.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Neodymium magnetic field meets nanocatalysis: a sustainable route to novel azines and condensed heterocycles.Scientific reports · 2026Article
- Design and synthesis of 7-chloroquinoline-derivative-bearing urea, carbamate, or thiourea moieties and their antimalarial activity againstFrontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial hybrids are compounds that can inhibit, stop the growth of, or kill microorganisms, including bacteria, fungi, and parasites. Antibiotics, a subset of antimicrobial agents, specifically target bacteria and include well-established classes such as β-lactams, macrolides, quinolones, and oxazolidinones. Other antimicrobial hybrids are designed for treating a wide range of diseases, including fungal infections, leishmaniasis, parasitic diseases (such as trypanosomiasis and malaria), leprosy, and tuberculosis. Some hybrids are designed to treat a variety of diseases. This review highlights studies primarily published between 2000 and 2023, with a few from 2024, underscoring the dynamic and rapidly evolving nature of antimicrobial hybrid research.
Indexed as
Identifiers
40765081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.